|
| << vorige | volgende >> |
Tijdschrift beschrijving
Alle jaargangen van het bijbehorende tijdschrift
Alle afleveringen van het bijbehorende jaargang
Alle artikelen van de bijbehorende aflevering
Details van artikel 81 van 105 gevonden artikelen
| Titel: |
Process for the development of vaccine against the hepatic stage of Plamodium vivax |
| Auteur: |
Sócrates Herrera Leonardo Victoria Olga Fernández Anilza Bonelo Blanca Liliana Perlaza Constanza Zapata Deidre Overgaaw Mauricio León Edna Galindo Nayibe Valencia Lina María Acuña Gustavo Quintero Nora Restrepo Juan Diego Vélez Fabián Méndez Adriana Villegas Giampietro Corradin Myriam Arévalo-Herrera |
| Verschenen in: |
Colombia médica |
| Paginering: | Jaargang 36 (2005) nr. 1 pagina's 5-15 |
| Jaar: |
2005 |
| Inhoud: |
Introduction: Plasmodium vivax causes approximately 80-100 million clinical cases every year. It is the most prevalent human malaria parasite in the American continent and its prevalence is second only to P. falciparum worldwide. Due to the emergence of medication-resistant parasites and an increase in insecticide-resistant mosquitoes, research to find a vaccine that could prevent or limit the clinical manifestations of the disease has increased greatly. During the last two decades, significant progress has been achieved in this attempt; however, the development of a P. vivax vaccine has been hampered due to the lack of sustainable in vitro parasite cultures. Objectives: We describe the development and testing of a vaccine to P. vivax pre-erythrocytic stages. We selected the circumsporozoite (CS) protein, an antigen abundantly expressed on the parasite surface. Methodology: After extensive immunological characterization in vitro, three long peptides (N, R and C) were synthesized, and the toxicity and immunogenicity of these peptides were thoroughly assessed in animals. To determine the safety and immunogenicity in humans, a randomized, double blind clinical trial was conducted. The trial included 23 healthy volunteers who received 100 µg of N, R and C of each peptide formulated in Montanide ISA-720 adjuvant. Conclusions: The vaccination was well tolerated and proven to be safe in both animals and volunteers; thus, additional clinical trials utilizing this vaccine candidate are indicated. |
| Uitgever: |
Corporación Editora Médica del Valle (provided by DOAJ) |
| Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
Details van artikel 81 van 105 gevonden artikelen
| << vorige | volgende >> |